JY
APYX icon

Jeff Yass’s Apyx Medical APYX Stock Holding History

Jeff Yass’s Portfolio APYX Stock Details APYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$971K Sell
216,263
-51,298
-19% -$203K ﹤0.01% 8276
2026
Q1 		$987K Buy
267,561
+65,910
+33% +$246K ﹤0.01% 7918
2025
Q4 		$706K Buy
+201,651
New +$703K ﹤0.01% 8008
2025
Q1 		– Sell
-28,450
Closed -$45K – 12413
2024
Q4 		$45K Buy
28,450
+15,380
+118% +$21.5K ﹤0.01% 11721
2024
Q3 		$16.2K Sell
13,070
-61,727
-83% -$77.9K ﹤0.01% 11663
2024
Q2 		$100K Sell
74,797
-106,516
-59% -$157K ﹤0.01% 11031
2024
Q1 		$247K Sell
181,313
-6,172
-3% -$13.1K ﹤0.01% 10142
2023
Q4 		$491K Sell
187,485
-64,345
-26% -$156K ﹤0.01% 8707
2023
Q3 		$806K Buy
251,830
+203,923
+426% +$950K ﹤0.01% 7133
2023
Q2 		$241K Buy
47,907
+20,631
+76% +$105K ﹤0.01% 9887
2023
Q1 		$78.6K Buy
27,276
+10,624
+64% +$31K ﹤0.01% 11444
2022
Q4 		$39K Sell
16,652
-65,297
-80% -$199K ﹤0.01% 11523
2022
Q3 		$368K Sell
81,949
-74,081
-47% -$530K ﹤0.01% 9286
2022
Q2 		$914K Buy
+156,030
New +$801K ﹤0.01% 6753
2021
Q3 		– Sell
-48,486
Closed -$500K – 12692
2021
Q2 		$500K Buy
+48,486
New +$480K ﹤0.01% 9592
2019
Q4 		– Sell
-17,153
Closed -$116K – 9657
2019
Q3 		$116K Sell
17,153
-19,912
-54% -$141K ﹤0.01% 9482
2019
Q2 		$249K Sell
37,065
-169,358
-82% -$921K ﹤0.01% 8681
2019
Q1 		$1.3M Buy
206,423
+85,148
+70% +$659K ﹤0.01% 4489
2018
Q4 		$786K Buy
121,275
+110,640
+1,040% +$670K ﹤0.01% 5145
2018
Q3 		$76K Sell
10,635
-1,045
-9% -$5.81K ﹤0.01% 8703
2018
Q2 		$51K Sell
11,680
-31,928
-73% -$118K ﹤0.01% 9269
2018
Q1 		$130K Buy
+43,608
New +$112K ﹤0.01% 8599
2017
Q1 		– Sell
-42,839
Closed -$142K – 8884
2016
Q4 		$154K Buy
+42,839
New +$191K ﹤0.01% 8835
2016
Q2 		– Sell
-19,023
Closed -$32K – 8501
2016
Q1 		$32K Buy
+19,023
New +$38.3K ﹤0.01% 8752

Other funds holding APYX

RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
ACM
Archon Capital Management Seattle, Washington $246M AUM 130.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EIM
Essex Investment Management Boston, Massachusetts $763M AUM 108.51% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
SBCM
Silverberg Bernstein Capital Management Armonk, New York $261M AUM 89.93% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
HKAM
Horizon Kinetics Asset Management New York $8.82B AUM 23.05% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jeff Yass's APYX Position: Q2 2026 in Review

Jeff Yass reduced its Apyx Medical (APYX) stake by 19% in Q2 2026, selling an estimated $203K and leaving 216,263 shares worth $971K. The position accounts for ﹤0.01% of the portfolio, ranked #8276.

Jeff Yass first reported a position in APYX in Q1 2016 and has held it in 24 quarters since. The position peaked at $1.3M in Q1 2019. 68 funds tracked by Wall St. Rank hold APYX as of Q2 2026.

  • Jeff Yass held 216,263 shares of Apyx Medical worth $971K as of Q2 2026.
  • Jeff Yass sold 51,298 Apyx Medical shares in Q2 2026, an estimated $203K.
  • Apyx Medical made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #8276 holding.
  • Jeff Yass first reported a position in Apyx Medical in Q1 2016 and has held it in 24 quarters since.
  • Jeff Yass's Apyx Medical position peaked at $1.3M in Q1 2019.
  • 68 funds tracked by Wall St. Rank held Apyx Medical as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.